All about HIV cure
NHMRC EL1 Fellow
No changes but a short follow up time. I’d be interested in following this cohort over time w longer follow up analyses
#IAS2025
No changes but a short follow up time. I’d be interested in following this cohort over time w longer follow up analyses
#IAS2025
Interestingly QVOA doubled over 5 years for women in the cohort pre- and post-menopause.
More evidence that female sex hormones impact reservoir. IPDA data coming
What an amazing job! Check out the recording for a really nice overview of the basic sciences presented here in Kigali
What an amazing job! Check out the recording for a really nice overview of the basic sciences presented here in Kigali
The investigators stress the importance of conducting mental health assessments throughout these trials
The investigators stress the importance of conducting mental health assessments throughout these trials
Social & behavioural research done as part of FRESH cohort #ATI study in Africa. So important to include this work w the biomedical analysis.
Family & partners of study participants underwent in-depth interviews - concerns raised abt risks
Their peptide pool able to trigger immune responses in transient virus controllers, response varies between donors
Their peptide pool able to trigger immune responses in transient virus controllers, response varies between donors
Josefina Marin presents on IMAP (immunoinformatic analysis pipeline) which selects peptides found within >85% Los Alamos database) - known as IMAP peptides.
Josefina Marin presents on IMAP (immunoinformatic analysis pipeline) which selects peptides found within >85% Los Alamos database) - known as IMAP peptides.
Briefly - promising but a while to go to address issues including lack of HIV antigens in PLWH on ART
I’ll be coming back to relisten to this talk!
Briefly - promising but a while to go to address issues including lack of HIV antigens in PLWH on ART
I’ll be coming back to relisten to this talk!
16 reviewed by safety monitoring committee and 2/3 had experienced viral rebound by week 12.
Possibly indicating subtype C virus not sensitive to the bNAbs?
Study stopped enrolment as per pre-specified criteria. Further virology immunology and reservoir data to follow
16 reviewed by safety monitoring committee and 2/3 had experienced viral rebound by week 12.
Possibly indicating subtype C virus not sensitive to the bNAbs?
Study stopped enrolment as per pre-specified criteria. Further virology immunology and reservoir data to follow
bNAb screening NOT conducted pre-enrolment
Primary endpoint again is viral rebound at 24w when therapeutic bNAb levels are still circulating - like RIO & Marina Caskey’s bNAb study presented yesterday
Here is the poster
Here is the poster
Our friends at @westmeadinst.bsky.social looked at cells from blood & pleural effusion fluid from people w HIV w active pleural TB.
TB coinfection impairs HIV specific CD8 T cells causing more genetically intact provirus in pleural effusion cells.
Our friends at @westmeadinst.bsky.social looked at cells from blood & pleural effusion fluid from people w HIV w active pleural TB.
TB coinfection impairs HIV specific CD8 T cells causing more genetically intact provirus in pleural effusion cells.
This poster from Duke Transplant Centre highlights the HOPE Act in USA: 500 transplants in PLWH receiving organ transplants from HIV+ donors.
This is a rich opportunity to biobank discarded lymphoid tissue from the operation for research
His team engineered a therapeutic from a natural process that causes viral load vascilations in plasma.
Tested in monkey model - single dose TIPS led to lower viral set point.
Track A #IAS2025
His team engineered a therapeutic from a natural process that causes viral load vascilations in plasma.
Tested in monkey model - single dose TIPS led to lower viral set point.
Track A #IAS2025
I think this was a TREATMENT study. 6 monthly dosing of LEN TAB and ZAB. 3 virological failures (but Joseph using the wording of viral rebound as if the participants underwent treatment interruption).
I think this was a TREATMENT study. 6 monthly dosing of LEN TAB and ZAB. 3 virological failures (but Joseph using the wording of viral rebound as if the participants underwent treatment interruption).